Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Pool Welcomes Long-Acting Injectables License

Tandem Nano Deal Offers Technologies For Malaria, Tuberculosis And Hepatitis C

Executive Summary

The Medicines Patent Pool has struck a deal with University of Liverpool start-up Tandem Nano to secure its first license for long-acting technologies for malaria, tuberculosis, and hepatitis C.

You may also be interested in...



Prestige Plans ‘Strong Price Competitiveness’ For Its Adalimumab Biosimilar

As Prestige BioPharma announced plans for Phase I and Phase III trials of its PBP1502 proposed adalimumab biosimilar, as well as expected filing dates in the EU and US, the company outlined how it believes its proprietary technology will allow its Humira rival to compete aggressively on price.

FDA Takes Cues From Feedback On GDUFA Research Priorities

The FDA has outlined how it has incorporated feedback on its GDUFA science and research priorities for FY2022 from a public workshop held earlier this year, across issues including harmonization of bioequivalence standards, nitrosamine impurities, and the use of AI to support generic drug development.

Mayne And Mithra Receive Australian Nextstellis Approval

Mayne Pharma and Mithra have revealed launch plans in Australia for their Nextstellis oral contraceptive that combines the novel estrogen estetrol with drospirenone, following approval by the TGA.

Topics

UsernamePublicRestriction

Register

GB151277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel